Herculean mistake: mephentermine associated cardiomyopathy

Phys Sportsmed. 2021 Feb;49(1):116-122. doi: 10.1080/00913847.2020.1763146. Epub 2020 May 13.

Abstract

Case presentation: A 32-year-old professional bodybuilder presented with acute decompensated heart failure. He gave a history of anabolic androgenic steroids (AAS) use for >2 years and mephentermine use for the preceding 3 months. Management: Transthoracic echocardiography showed severe left ventricular (LV) dysfunction with a large pedunculated, mobile thrombus attached to the ventricular apex. The patient had an embolic stroke during the hospital stay, with complete neurological recovery. Following the cessation of mephentermine use, there was a steady improvement in LV function over a follow-up of 2 months. However, at 3 months, his ventricular function showed deterioration, which coincided with mephentermine reuse. Take home message: Though AAS abuse by athletes leading to such a presentation has been documented, to the best of our knowledge, a similar role of mephentermine has not been reported.

Keywords: Mephentermine; anabolic androgenic steroids; toxic cardiomyopathy; ventricular thrombus.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cardiomyopathies
  • Echocardiography
  • Embolic Stroke / chemically induced*
  • Embolic Stroke / diagnostic imaging
  • Humans
  • Male
  • Mephentermine / adverse effects*
  • Performance-Enhancing Substances / adverse effects*
  • Recurrence
  • Testosterone Congeners / adverse effects*
  • Ventricular Dysfunction, Left / chemically induced*
  • Ventricular Dysfunction, Left / diagnostic imaging
  • Weight Lifting*

Substances

  • Performance-Enhancing Substances
  • Testosterone Congeners
  • Mephentermine